HAPPENING NOW
The headlines, minus the noise. Updated in real time. Beta
FDA approves label expansion for Vyvgart, Vyvgart Hytrulo for generalized myasthenia gravis
The U.S. Food and Drug Administration has approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigim…
AI Summary Powered by Happening Now AI
The U.S. Food and Drug Administration has approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with (gMG). The expanded approval was granted to argenx.
Read full article on MedicalxpressAI summaries can be wrong sometimes—always verify important details using the source article.